Previous 10 | Next 10 |
JERUSALEM , Feb. 25, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in March. Cowen 40th Annual Health Care Conference Date:...
Intec Pharma (NASDAQ: NTEC ) has priced its public offering of 16.25M ordinary shares and warrants to purchase up to same number of ordinary shares at $0.40/share, for gross proceeds of $6.5M. More news on: Intec Pharma Ltd., Healthcare stocks news, , Read more ...
JERUSALEM, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares (which includes pre-funded warrants to purchase ordinary shares in lieu...
Intec Pharma (NASDAQ: NTEC ) is down 20.3% on heavy after-hours volume following its announcement of a proposed public offering of ordinary shares and warrants. More news on: Intec Pharma Ltd., Healthcare stocks news, Stocks on the move, Read more ...
JERUSALEM , Jan. 30, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordin...
JERUSALEM , Jan. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill ® platform, in a Letter to Sh...
The following slide deck was published by Intec Pharma Ltd. in conjunction with this Read more ...
JERUSALEM , Dec. 11, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill ® (AP) for a proprietary Novartis co...
JERUSALEM , Dec. 6, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will be participating in the 12 th Annual LD Micro Main Event investor conference. 12 th Annual LD Micro Main Event Dat...
JERUSALEM , Dec. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicag...
News, Short Squeeze, Breakout and More Instantly...
Intec Pharma Ltd. Company Name:
NTEC Stock Symbol:
NASDAQ Market:
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, was proud to unveil its poster at the 2024 Annual Meeting of the American Association for Cance...
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural killer cells, dendritic cells, Th1 CD4, and CD8 T cells NEW YORK, March 25, 2024 (...
“Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey Meckler Registration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical stage biotech...